Increased Safety Concerns Could Reduce Drug Development Pipelines By 20%, IMS Says
The pharmaceutical research firm cites increased regulatory scrutiny and post-marketing commitments as catalyst.
The pharmaceutical research firm cites increased regulatory scrutiny and post-marketing commitments as catalyst.